nep

Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal

Candoxatril (UK 79300) 是具有口服活性的中性肽链内切酶 (NEP，EC 3.4.24.11) 抑制剂，可改善接受血管紧张素转换酶抑制的慢性心力衰竭患者的运动能力。

Thiorphan 是选择性neprilysin 抑制剂 (IC50:6.9 nM) 。

Racecadotril (Acetorphan) 是一种中性内肽酶 (NEP) 抑制剂，具有止泻作用。Racecadotril 及其活性代谢物 Thiorphan 抑制小鼠脑中纯化的NEP 活性，Ki 分别为 4500 和 6.1 nM。

Sacubitril hemicalcium salt (AHU377 calcium salt) 是一种有效的 NEP 抑制剂，IC50=5 nM。它是研究心力衰竭药物 LCZ696 的组分之一。

Sacubitril (AHU-377) 是一种有效的NEP 抑制剂，IC50=5 nM。它是研究心力衰竭药物 LCZ696 的组分之一。

SCH 42495 is an orally active neutral metalloendopeptidase inhibitor. SCH 42495 is the orally active ethyl ester prodrug of SCH 42354.

SCH 42495 racemate is the racemate of SCH 42495. SCH 42495 is an orally active neutral inhibitor of metalloendopeptidase (NEP), with antihypertensive effect.

SQ28603 is a potent and selective neutral endopeptidase 3.4.24.11 (NEP) inhibitor.

TD-0212 is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).

Omapatrilat is a metalloprotease ACE and NEP dual inhibitor (Ki: 0.64 and 0.45 nM, respectively).

Phosphoramidon Disodium (Phosphoramidon Disodium Salt) Salt 是一种金属蛋白酶 (metalloprotease) 抑制剂 。Phosphoramidon Disodium Salt 抑制内皮素转化酶 (ECE) ，中性肽内切酶 (NEP) 和血管紧张素转换酶 (ACE) 的IC50分别为 3.5 ，0.034 和 78 μM。

NEP-IN-2 is an inhibitor of neutral endopeptidase. It also is used in the research of proliferation in atherosclerosis, restenosis.

NEP(1-40), N-terminal uncapped 是 NEP(1-40) 的类似物，但其 N 端未进行乙酰化修饰。NEP(1-40) 是一种 Nogo-66 受体 (NgR) 的肽类拮抗剂。

NEP-28 is an AR agonist. NEP28 is a new SARM exhibiting high selectivity for androgen receptor. NEP28 showed tissue-selective effect equivalent to or higher than existing SARMs. In addition, the administration of NEP28 increased the activity of neprilysin, a known Aβ-degrading enzyme.

NEP(1-40) TFA 是一种Nogo-66 受体 (NgR) 的肽类拮抗剂，其作用机制为通过抑制髓蛋白所引发的损伤逆转，限制小胶质细胞形态分布的变化。

Sacubitrilat (LBQ-657) 是活性的脑啡肽酶 (NEP) 抑制剂。

NEP-IN-1 是中性肽链内切酶 (NEP) 的抑制剂 (IC50 = 2 nM)。

TAT-NEP1-40是一种能够穿透血脑屏障的多肽。它能够保护PC12细胞不受缺氧和葡萄糖剥夺(OGD)所致的损伤，同时促进神经突的生长。此外，TAT-NEP1-40通过阻断缺血性脑损伤中的细胞凋亡，对缺血后的神经功能恢复具有积极作用。该化合物适用于中枢神经系统损伤，特别是中风后的轴突再生与功能恢复方面的研究。

TAT-NEP1-40 TFA 是一种能够穿透血脑屏障的多肽。它能够保护 PC12 细胞抵御缺氧和葡萄糖剥夺 (OGD) 的损害，并促进神经突的生长。此外，TAT-NEP1-40 TFA 可通过减少缺血性脑损伤中的细胞凋亡，以改善神经系统功能。该化合物在中枢神经系统损伤，包括中风后轴突再生及功能恢复的研究中具有潜在应用价值。

TAT-NEP1-40 acetate 是促进脑卒中后轴突再生和功能恢复的候选分子。该化合物能够抵御PC12细胞的氧和葡萄糖剥夺(OGD)损伤，并促进神经突生长。它通过抑制神经元凋亡(apoptosis)作用，保护大脑免受缺血再灌注伤害，并能有效传递至大鼠的脑内。

MPT0B098 is a potent microtubule inhibitor through binding to the colchicine-binding site of tubulin. MPT0B098 is active against the growth of various human cancer cells, including chemoresistant cells with IC50 values ranging from 70 to 150 nmol L. MPT0B098 arrests cells in the G2–M phase and subsequently induces cell apoptosis. In addition, MPT0B098 effectively suppresses VEGF-induced cell migration and capillary-like tube formation of HUVECs. Distinguished from other microtubule inhibitors, MPT0B098 not only inhibited the expression levels of HIF-1α protein but also destabilized HIF-1α mRNA. The mechanism of causing unstable of HIF-1α mRNA by MPT0B098 is through decreasing RNA-binding protein, HuR, translocation from the nucleus to the cytoplasm. Notably, MPT0B098 effectively suppresses tumor growth and microvessel density of tumor specimens in vivo. Taken together, our results provide a novel mechanism of inhibiting HIF-1α of a microtubule inhibitor MPT0B098. MPT0B098 is......

Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.